中国丙型肝炎防治指南(2015年更新版)_图文.

1、Y9G219611963EE凰介e east一 .RWt*flt“Mi A” 一 M4B 9 .1965 rFBAM9 wawi x ”AB4UB dMtU(MUM lwM f NMW MtMa ar aeamiw M.Wi n Q amtw MRM二rM4 o z C.KVMea r* tu.RiscAa f x -waMenaXIfMaoMi Mt,*MeM fwaacwr- oteowa ”-HMWOB Kr 4十亠 .Ill , 二 k. Mfl* y * ”*15 n、 s M * te w环 e !* Mt & A rM 、VMM . JW ” itbHfaw、。小 Z W !*c

2、 “! BMi二-w、a 19C7 AAA M*U M尸fA 3 !”，wuto!* I - *i M4 . ! M受 ey “ i me Q.6a” 2.4* ym g9ff e VROMVVtW VW v WM BMteWMW . rwf rBS 0MilM(X yaae i e I MB* ” Mi* a、 L eMl RMi 4Asa u #_侦 yvf 育介 Mil、 W” vwMfM4iae*MB * k*”M MkAM.W、鼻”- *wat*FT IMIut. BIB twvem aetfrMTWMI 4 * Ifm w y空wi.a|ift. eym v vw,q.5 ree4

3、44MeMKw rr ee*”ez *mw MM ci un 9w ”K r a as” “!J 1I TMMrvx 1951976临床肝胆病杂志第31 卷第12期2015年12 月J C1 in H ep a t o 1 , Vo1 .3 1 No1 2 ,Dec .2 01 5tio n J .G ast r oentero 1 ogy ,201 214 2( 6 ):1335 1 339 4 8 G EDF EL L AYJ , T H O MPS O NAJeta 1 .Ge ne ti cv ar i a t i o nin I L 28B pred i ctshe pa ti ti

4、 sCt r e a tme n t - in du c e dvi ra 1c 1ear a n c e J Nature2 0 0 94 6 1(72 62):39940 1 49E ur op e an As so ci a t i o nf or Study ofLiv er；As oc ia ci o nL a t i noa mericanapar ae 1E stud i ode 1 H ig ado EA S L- -A L E HC1 i ni ca1P r a c t i c eG u i de1in es:N-on i nv asiv et e s t sforeva 1

5、u atio n of 1i verdiseaseseveritandprognosis J .JHepatol,2 015,63( 1 ): 23726 4.50 WA I CT,GREENSONJ K,FONTANARJ,e ta l .A s imp l e n o n i nva s i vei ndexc anp redictboths i g n i f icantf ibrosi sa n d c i rr h o s i si npatients withc h ro n i che p at i tisC J . H ep ato lo gy,2003,38(2):51852

6、6. 51 Rev i ewP ane l forLiverSt i f f n essMe asu re ment.Recomme nda t i on sfo rt h eclini c a l a pp l icatio noft ransi entelastographyi n J .C h i n JH e p a t ol,20 13, 2 1 ( 6 ): l iv er fibros isa ss essme n t 420 42 4.( i nCh ine s e).肝脏硬度评估小组.瞬时弹性成像技术诊断肝纤维化专家意见J.中华肝脏病病杂，2013,2 1( 6):42042

7、4.52 Mi n i s t ryo fHea l tho f thePe o p l esRepubl i co fCh i na.Upda t e ds tandardsforthed i a g n o s i sa n dt r ea tme n to f pr imaryl ivercancerJ.ChinJHepatol,2 012,2 0( 6 ): 4 19 4 2 6 .( i n ) C h i n e s e中华人民共和国卫生部.原发性肝癌诊疗规范（20 11 年版）摘要J .中华肝脏病杂志，201 2 ,2 0(6):4 1942 6 . 5 3MA R T INI

8、A ,FA T T O VIC H G , GU I D OM,e t a l . H CV gen ot y p e 3an d s q ua mo u sce l l c a r cino maan t i g en( S CCA) I g M ar e i n d e pende nt l ya sso ci a te dwi t hh i s t o l ogi ca lf e a t ure s o f NA S H i nHC V i n f ectedpatients J. JV i ralHepat, 2015,2S , MA I D AM,C A MM ? C ,etal.S

9、teatosisa2014,61(3):523529. t i t i sC 55POYNARDT,MO U S SALL I J ,MUNTEANUM,et al .Slo w r e g r ees si o no f l iv er f ibro si spres u me dbyr epe at e dbi om a rker s J.aft e r vir ol o gi c a lc ureinpa ti ents w i t hc hro niche p a ti tisC JHe pa tol20 13,5 9 (4 ):6 7 5 6 83 .56 MOH A NP ,BAR

10、TO NBA ,N A R K EWIC ZMR,etal.Evalua tingprogressionHepato logy, 2 0 1 3,5 8( 5 )LAME RECH TRW,S T E R L INGRK,NAI S H A D H A MD , e t a l . I r o nl evelsi nhepatocyte sa n dp o r t a l t r a c tc el lspredictpro g re s s i onandou t comeso fp at i e n t swi t ha d v an c edchro n i ch e p at i t

11、i sC J .Gastr o en terology,2011,140(5):1490500.58 DAMEROSIOR,AGHE MO A ,F RAQUEL2(10)800808.54MA C A L U S OFff ectsthe perfti ffnessmeasurisassess mentinormance o f liverse m entfor fibrosp atientswit hg e n och e p aofliverdiseasefromr e p e a tesinchildrenwithchroniche p a t i t i sCetrospect i

12、v es tudy0 1 5 8 6.57t y p elch r o n iJ . JH e p a t o l ,L I M,e tal.Thediagnost i caccu rac yofFibroscanforc irrhos isi si n fluence dby liv er mor p h ometr yinH C Vpatien ts withas u sta i ne dvir o l o g i J . JHep ato l ,2 013,59 (2):2 5 1 25 6ca lre spo ns e 5 9 A KHT ARE , MA N N EVS A AB S

13、 .C ir rhosisr egress ion inhe pat itis Cpa.ti e : n tswith s ustai n ed virolo gi ca lr es pons eafter an t iv ir alth er a py: am eta 一 ana lysi s J. LiverInt201535(1):30 一 3 6 .60 DA MBR O S IORAG H E : MOA ,Ru MIMG,et a a1 .Amor phom etric and immun o h ist oche micalst ud ytoa ss es sthe b en e

14、fitofa su stained vi rolo gica l res po nse inh epatitis C vir u spaJH epato log y201256( 2 ):532 t ient swi thc i r r h o s i s543.61 BEDOS SAP,POYNARDT.Ana l g o r i th mf orthegradingo fact i v i t yi nc h r o n i ch e p a t i t i sC.TheMETAVIRCo ope rativeStudyGroup J .Hepatolog y ,1996,2 4 ( 2)

15、 :289293.62 K I MSu , OHHJ,WAN L E S SIRetal.Th e Lae nne cst agi ng s y s t em forhistologica l s ub cl as s i f i cation ofcirrh osi si su sefu l f o r stratification ofp rognos i si npa t i en t swi t hl i v e r cirrh0sisJ JHePat0 1 ,20 12 ,57( 3 )5 56一 5 63 631H UA NGYd eB O ERWEA D A MSL A ,e t

16、 aa1 .I mag ean a1 ysi s0 f1 iV erbi 0P s ysamP1 esmeas u re sf ibr0 sis an dpr e d icts c1i ni ca1 J JHePa t01 , 201461 (1)2 2一27 0 utc0 m e 6 4 D INGH ,MAJJWAN GWPE TAL A s se s s ment0 f1 iV erf ib r0sisT he r e1 a t i0nsh iPbe tw e en p 0 intshearw aVee 1 ast0 graJ 1 JG a str0 enter0 1P h yandqu

17、 an tit at iV ehist01 0gi c a1 ana.1ysis ,2015 , 3 0( 3 )5 53 一 5 58 H eP at016 51J oH:N-B AP T IST E A AT O MLIN S ONG ,H S UP C ,e ta 1S ust a in e dres P0 n d ershaVe b etterqua1 i ty 0 f1if eandP r0d u ctiVityc0m par e dw i t htr eatme ntfa i1 u res 1 0 ng aft er antiVira 1 the raPy f 0r J A m J

18、G as t r 0enter0 120 0 91 04(1 0)243 9一 hepatit isC2448 66B UN C H O RN T A VA K ULC,MAN EE R AT TA NA Po R NM,C H A V ALI T DH AMR O N GD Mana g em ent 0 fP a t ients w i th hep ati tis C infec ti0 nandr r en a 1 dis e as e J W0r1dJH e p at0120 157(2) 21 3一 22 5 6 7 E L 一 SH A BR A WIM ,H AS S AN I

19、NF T rea tmeent0fheP a ti tisBa n dCin chi1dr e n J 1 M inerVaPe d i atr ,20 1 4,66(5):473489.68 MORGANRL,BAACKB,SMI THBD,e ta l.Erad ic at io nofhepat i t i sCviru si nfectio nandthed eve1 o p me nto fhepat o ce1: ame t aa na1 y s iso fobse r v at i o na 1 studies 1 u 1 a r c a r c i n o ma J. A nn

20、ln t er nMed ,2 0 1 3,15 8(5Pt1):3 2 9 33 7 . 69B A C K U SL I,BOOTHROYDDB,PHILLIPSBR,e t a 1.As u s t a i n e dv iro1ogicrespons ereduce sr i s kofa 11c ausemo r t a 1 ityinpatientswithhepatitisC J.C1inGastroent ero1Hepato 1,2 0 1 1,9( 6 ):5 0 9 5 16.70 WEIL,LOKAS. Impactofnewhe p a t i ti sCtreatm

21、entsi ndif fe r ent reg ionsof thewo r 1d J . G a s t r o entero1ogy,2 0 1 4,1 4 6( 5 ):1 1 45 115 0 .71 NAKAMOTOS ,KANDAT,S H I RASA WAH ,e t a1 .A n ti vir a 1therap ie sforchronichepati t i sCv i r u si n f e c ti o nwi t hcir r h os is J .Wor 1 dJH e pato1,2015,7(8):11331141.72BOCCAC C I OV, BRU

22、NOS.Ma n a g e me n t o f H C Vp a t i e n t sw i t h c i r r h o s i sw i t hdi rectactingant ivira1s J .LiverInt,2 014,34 (Supp1 1):3845. 73 K O N E R MA NMA , ME HTASH,SUTCLI FF ECG,eta1.F i b r o s i sprogress i o nin hu m animmuno d efi ci enc y virus/hePatitis C:ProsP ec t ive ana 1 ys isof 43

23、5 1 iv erbioPvir us coinfec teda du1tssy pairs J .He P ato1 og y20 1459( 3):767 一 77 5 .7 4K ON S TAN TI N O U；DD EU T S CH M. T he:sP ec tr u m ofH B V /中华医学会肝病学分会， 中华医学会感染病学分会丙型肝炎防治指南（20 1 5年更新版）1977HCVcoinfcction:cpidteimio1voig yrac11iinntiecraa1ccth:iaornascatne r id masncsa ge m en tJ .A nnGas

24、tr o entero 1 ,20 1528(2)2 21一22875 MICHELO TT IG AMA C H A D O MVDIE HLA M.N A FLDN A S H J .N atRe vGas troente r o1H e Pa to120 1 310 an d 1i vercan c er(11):656一665 76MON JE- -A G U DOPC A S T R O 一 I G L ESIA S ARI VE R O JU ? RE zAeta 1.Im PactofH I Vinfec t i o nonsus taine dviro 1o gi ca1res

25、Ponse to tre atment again st h ePatit i sCv irus w ith Pe gy1a te d in terfer o nP1usr ibavirin J Eu rJ C 1inMic ro bio 1 InfectD is20153 4(10 ):1 92 9一19 36. 77 MAR IOOMC ,FO R N SX . He Pa titis C tr eatm entf o rPati e ntspost 1 i v e r t ranspl ant J .CurrOpi nOrganTransp lant, 2 0 15,2 0(3):25

26、1 258.78 CHARLTO NM, G ANEE,MANNSMP, e t a 1 . Sofosbuvi randribavirinfo rtrea tmen tofco mpensate dre cur re n thepat it isC J.Gastroentero1ovirus in fe ction after 1 ivertran sp 1ant at io ng y201514 8( 1):108 117 79 AG N EL LOV,C HUNGR T,K AP LANLM.Ar o 1 ef o r h e pati t i s J .NEnglJCvi rusinf

27、ect i o ni nt ypel Ic r y o g 1 o b u 1 i n e mi a Me d , 1992, 3 2 7 ( 2 1 ): 1 4 9 0 1 4 9 5. 80CACOUBP,TERRIERB,SAADOUND.Hepa t i t i sCv i ru s:t he rapeut i co p t i o n s J .AnnRheumDi s , induce dvascu 1 i t i s 2 0 1 4 ,7 3 ( 1 ):2 4 3 0.81 JOH N S O NR J , GRETCHDR, YAMABEH, e t a1. Membr a

28、 n opro 1if e rat iveg1 o meru 1 on ep h r i t i sasso cia t edwit hh epati t i sCv i r u si n f e c t i on J . NE ng1 JMe d, 1 9 9 3,3 28(7 ) :4 6 5 4 70. 82 PA YD A SS.H e p ati t isCvi r usa n d1y mp h o ma J . Cr i tRevOnco 1Hema to1,2015,93(3):246256.83 DESOUKYDE,KASE MYZ ,ABDEL HAMIDAE,e t a 1

29、 .I n s u 1 i nr e s istanceandpredia b e t e si nh e p a t i t i sC v i r u sp a t i e n t s J .AmJMe dSc i, 2 0 1 5, 3 5 0 ( 2 ) : 7 780.84 ZORNITZKIT, MA L N I C KsL Ys Y YLeta1 Inte rf e r o nth era JPyin heP a t itisC1 e a d i ngto c hr onic ty Pe 1di a b etes W o r 1 dJGa str oenter o12015 ,2

30、1(1 1 ):2 3 3 2 3 9.85 G IsB ER TJP ,G AR C ? A B U E YL ,P A JAR Es JM,eta1 . P :reva:1e n c eo fh eP a ti tis C vi ru sin feet io n i np o r ph yri acutan ea tard as y stemat i er e vi ew a0 033 9( 4 ):6 20一627 .86R A CC IAT T IDGOR GO R E TTIV ,sE PEDE G ,e ta1 An It a1ia nstudyon he a 1th r e1 a

31、te d q ua1 ity of1ifeand fatig ueinpatie nts w it h chron i cfa t i guesy nd rrusinfec t ion :siffe re ncesJ I n1 Ph ar m ac o 120 1 11 87 X UCJZ HA1 Pre va 1e ncean dion of he pa titis Bion si n ane ed 1e- sn inNorthe rn C hinmi1a r it i e san dd it JImmun o p at h oN GCP,L U OB F,e t ac h ara ct e

32、r i z a ta n dC v i r u sin f e c th a ri n gp o p u1 a t i oa J B MC P ub 1 i c Hea1 th2015 ,H O W EPZ H A OPn m igra ntsa11ytr ans mi t:asys tem a t15 :46 0 8,eta 1 Rurar ea thi ghrit ed a nd virai cr evie w a n1ts ko1 h et he h r o n icH C V vo mea n dp a tent swi124(3):67368dme t a a n a8 Z O UX

33、 ,Cn d m eta -an a1y s i s JJH e p a to 121 y t isi nfect ionsinChi nas i sJ .BMCI n fectDi s, 2014,14:490.8 9 LAMBERTJ,JACKSONV,COULTER SMI THS ,e t a 1 .U n i v e r s a 1 a n ten a t a 1 s c r e e n i n gf o rhepat i t i sCJ .I rMedJ, 2013,1 0 6(5): 136139 . 9 0 F I SS ELLRB,BRAGG GRESHAMJ L ,WO O

34、 D SJ D ,e t a 1 . Patternso f h e p a t i t i sCp reva1enceands eroconve r si oninhe :t h eD O P P S J .Kidmodia1y sisu ni tsfromthreecont inents,20 0 4,65( 6 ) : 233 52 342. n eyl n t91P OS TJJ ,A R A I NA ,L L O Y DA R.E n hanci nga s s es sme nt and J . C 1 i nI nt reatmentofhepat i t i sCi nt h

35、 ec u s todi a1 sett ingfectDis, 2 0 13,5 7(Supp12):s70 s74.92 L E I D N E RAJ,CHESSONHW,XUF,e t a 1 .C o s t e f f e c t i v e nessofhepati t i sCt r e a t m entforpat i en t si ne a r 1 ys t age so f J .Hepato1 ogy, 2 0 15,6 1( 6 ):1860 1 8 6 9.1 iverdisease 93 P U O T IC,B ELL I SL,GUARI SCOR,e t

36、 a 1 .H C Vc a r r i e r swi t h n o r ma 1 a 1 a n i n ea mi n o t ransferase1 e v e 1 s :h e a 1 thyperson so r seve re 1yi 1 1patients?Dea1 i n gwi thane very dayc 1i n i c a 1 p r o b 1 emJ.EurJInter nMe d ,2 0 10,2 1( 2 )5761.94 EuropeanAs soc i at ionf o rtheS tudyo ftheL iver.EASLC 1 ingiecme

37、an1tPorfahcetpiacteiGtuiisdCev1iirnue ssinmafneact io n J JH ep ato120115 5(2 ):24 5 264 95 C hinese S ocietyofIn fe ctio us Disea sesan dP arasi to 1o gyan dC h ine seM e d ica1A ssoc iaC hi nese S ociety ofHepato1 ogy ti on G uid e1in es ofpre ve ntion an dtreat mentf orhepatitis C J . C h in JHep

38、a to1200412(4):19 4198.(inChinese）中华医学会肝病学分会、 中华医学会传染病与寄 生虫病学分会.丙型肝炎防治指南J .中华肝脏病杂志，20 0 4,1 2(4) :194一 198.9 6C hine s eN ati ona1 Formu1ar yCo mmit t ee Chinana tion a1 prescri pt io nsetM .Bei jing :Pe op1ezsMi1 i taryM ed i c a 1Pu b1is hin g2 01 0 .(i nC h in es e ) H ou s e中国国家处方集编委会.中国国家处方集 M.

39、北京：人民军 医出版社，2010.97 WE IL.HepatitisCclini c a 1 di a g n o s i sandt reatmentmanu a 1 M . B e i j ing:SciencePress, 2 012.(inChinese)魏来.丙型肝炎临床诊断与治疗手册M.北京：科学出版 2 0 12 .社，98 KERSHENOB ICHD,MU OZL,MAL ?R ,e t a 1 .P r o c e edwi thcaut ion: peginterferonalpha 2aversuspeginte rferona 1 f a 2b inc hron i

40、ch epat i t i sC. As ys t e ma ticreviewo frandomizedt rialsJ. Hepato logy, 2 0 1 0,52(6):2 2 40 - 2 2 4 2.99 CHENXY,SHANGJ,YANGRF,etal.Hig hs u stai n edv i ro l o gi c a l r e s p o nset oop ti miz e dthe rapyf o rr e frac torychronichepat i t i sCt r e a t me n t n a i v ep a t i ent s : amult i

41、center random izeds tudy J .C hinJHepatol,2015,23 ( 6 ): 4 1 2 4 17.( i nChi ne s e )陈新月，尚佳，杨瑞锋，等.难治性慢性丙型肝炎初治患者优化治疗后的病毒学应答率研究J .中华肝脏病杂志，2 01 5, 23(6) :4 12417. 100EuropeanAs s o cia tionforStudyo fLiver.EASLCl inicalPrac t iceGuidel ine s :ma n a geme n to fh e p at i t i sC v i r u si nfect i o n J

42、 .JHepatol,2 0 14,6 0(2):392420.1 0 1RAOHY, YANGRF,S H A N GJ ,e t a l . Thee f f icacyandpro g nosticpredictorso fdif feren tt re atmentc ou r seswi thp egy l ate di nterferoncE2 aa n dr i b a v i r i nc omb i n a t ioninr e cu r rent J .ChinJIn t ernMed ,20 15,c h r o n i ch e p a t i tisCpatients

43、54 ( 8 ) :69 9 7 04.(inCh i n e s e )1 9 7 8 临床肝胆病杂志第 3 1卷第 12 期 2 0 15年 12月JCl inHepatol, Vol. 3 1N o .12, Dec.2 01 5 饶慧瑛，杨瑞锋，尚佳，等不同疗程聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎复发患者的疗效比较及影响因素J 中华内科杂志，2 0 15，5 4(8):699 704 1 02 1S IN GA LAG， WAL JE EA K，S HI FF MA NM， e ta1 Met a a: re一 t reat men t of g e no ty Pelh e P

44、a ti tis Cnonr esP o nna 1y sisd er san dr e1a P ser saf te rfai 1i ng in te r fe ro nan driba vir i nc o mbin at io nthe ra Py J 1 A 1 im e n tP ha r maco 1 Th er ，2 01 0，32( 8 ):9 69 9 83 :10 3 1S HA NGJX UX Y，C H ENX Y : ,eta1 Ef fi ca c ya nd re1a ted f a， ct ors o fP eg y1 ate di nt erfe ro n a

45、 2ap1 u srb a viri nt h er aP yfo r J1 Chi nJC 1 i nI nfe ( c tc h ro ni chep a ti t is Cin n onr resPo n der sD is2 01 58(3):23 2 -23 7 (inChi nesc）尚佳，徐小元，陈新月，等.聚乙二醇干扰素 a 2 a 联合利巴韦 林治疗慢性丙型肝炎无应答患者的疗效及影响因素J 中华临床感染病杂志，M ?C2msn0Cer o1Anin-5Bt bIwa r8Bive(B tis3 )OGhPenn2Bgod3Ryfe2 2Ttrt3Eeoo7Fdniiin1e

46、tn t ch te0aeer41rPf1 RCAMO1crNahseriototnrniPeP1a1stuCfaeetrrPious ribavi rin:a m e ta一 a na 1y J1 J He P ato 12 00951(4 ):67 5 -68 1sis1 05 1WEILHA NTY A N GD，eta1S imePrevir P1 usP eginter f eron /riba virinin tre atm ent一 nave Pati ent swi thchroni chepa t it i sCv i rus ge no typeli n f e c t i

47、 o n :re s u1 tsfromt h ep h as eETIGERs tudyconductedi nEastAsianpatientsl iv ingi nCh inaandKorea J .Hepatol Int, 2015, 9:s 6 1 . 1 0 6 LAWITZE,MANGIAA,WYLESD,e t a l.Sofosbuvi rforprev i o u s lyunt reatedc hron i ch e p a t i t i s C i n f e c t i o nJ.NEng1JMed, 2013, 368( 2 0 ):1 8 7 8 - 1 8 8

48、 7.107 MI S H RAP,FLORIANJ,QIK,e tal.FDAperspe c t i v eo n s o f o s b u v i r therapyforpa tientswi thc h r on i ch e p a ti t isCv irusgen o t y pe1i n f e c t i o nwh odidn o t respon dt otreatmentwi t h p e gyl atedinterferonandr i b a v i r i n J .Gas troenterology, 2 0 1 4,1 4 7( 6 ) :1 1 96-

49、 1 2 0 0 . 1 0 8 A F D H A LN , ZEUZEMS,K WOP , e t a l . Ledipasv i randsofosJ .NEnglJbuvi r foruntreatedHC Vgenotype1i n f ec t i onMe d, 2 0 14,370( 2 0 ):1 8 8 9 - 1 8 9 8.109 A F D H A LN ,R E D D YK R ,N E L S O ND R,etal.Ledipa s v i r a n d J . sofosbuvi rforprevi ous l y treatedHCVgenotype1

50、i nfectionNEng l JMe d, 2 0 1 4,3 7 0( 1 6 ):1483 - 1 4 9 3.110 K O WD L E YK V , GORDONSC, R E D D YK R , e t a l . Ledipasvi rands o fosbuv i r for8o r 1 2we eksf orchron icHCVwi thou t c i r r h o s i s J. NEnglJMed, 2 0 1 4,370(20):18791888 . 111 FELDJJ,KO WD L E YK V ,C OAKL E YE ,e t a 1 . T r

51、 e a t me n t o f H C Vwi t hA BT 4 5 0/romb i tasvi randd as abuv i r wi t hr i b a v i r i n J . NE ng 1 JMe d , 2 0 14, 370(17) : 15941603. 112 F E RENCIP,BERNSTEI ND ,LALEZARIJ,e ta 1 . AB T 4 5 0/ r omb i t a s v i randdasabuv i rwi t ho rwi t h o u tr i b a vi r inf or H C V J . NE n g 1 J Me

52、d ,2 0 1 4,3 7 0(21):19831992.113 ZEUZEMS,JACOBSONI M,B AYKALT,e ta 1 .R et r eatme n t o f H C Vwi t hA B T 4 5 0 / r omb itasv i randdas abuv i rwi thr i bav i r i nJ .NE ng 1 JMe d , 2 0 1 4, 3 7 0 ( 1 7 ) : 1 6 0 4 1 6 1 4 . 1 1 4 ANDREONEP,COLOMBO MG ,ENEJOSAJV,e ta1.ABT 450,r i t oGastroente r

53、o1ogy,2014,147(2):359365.115DF,HEZODEC,TRINHR,e t a 1 . A B T 4 5 0 / r o mb i t a s v i randdasabuvi r wi t hnavirombitas vchiev es 9 7 %and 1o1ogicres Po nseavirin in treati rand dasabuvir a0 0%s ustained virwith orw itho utribment一 eX Perienc et hHCVg en ot ype 1 bi n f edpatientswiribavi rinforh

54、epati tisCwi thJ.NEnglJMcd, 2014,370(21):19731982. cirrhosis 116R R E SM, e t a 1 . Dac latasvi rpl uss of osbuvi rforprevious lyt reatedo r u n t reatedchron i cH CVi n f e c t i o nJ.NEng1JMed,2014,370( 3 ):2 1 1 2 2 1.117 K U MA DAH,SUZUKIY,I K E DAK,eta1.D ,ac1ata svi r p1 u Llsas una pr ev irfo

55、 rchronicH C Vg e n ot y p e1b inf ec tion JH e pato1 o gy201 45 9(6 ):2 083 2 091.1 18 WEIL ,Z H A NGM,X UM,et a1 Da c1 ata s vi ra ndasu na pr evir in non 一 J ap a n es e A si anpat ie nts w i th( 二 hron icH C Vgen ot ype1bin fecti onhoar ein e 1 igi b1 efo r or in to1e r anttointer: pha se3fero n

56、a1 fa t h eerapie swit hor w ith out ri ba virin J . H epa to 1 ogy20 1562 :1 39 1 S VR12 i nteri mre su 1t s 1 19 L A WIT ZE ： ,G A N ：EE J.S o fo sbuv irf or pr evio u s1y un tre ated J. NEng 1JMe d20 1 33 69chro n i ch (pat itisCin fecti on( 7 ):67 8 679. 12 0ZE UZ EMSD US H E IKOG M,SALUP E， R一

57、EReta 1.Sofo sb u vi ran d r i ba vi ri ninHCVgenotypes2a n d3 J . N E n g 1 J Me d ,SKIMS,GARDINERDF,RODR I GUEZ TO20 14370(21):1 99 3 2 0 0 1.1 21 PO L SR ED D YKR, B A -Y K ALT , e t a 1.I n ter feron 一 fr e er egi me n so f o mbit asviran d AB T 一 4 50 /rwi tho r wi thout riba vi:PE A R L 一Iri n

58、i npa t i e nts withH C V g en oty pe 4 inf e c ti o n s tu dyre su1 ts J . He p ato 1o g y,2 0 146 0 : :1129. 1 22 GA N EEJ ,H YL A N DR H ,AND ,eta 1.E fficacy of Le d ip a s v ir ,Wit hor W it h outRi bav ir i n,f o r 12We e k sinan d So fo sbu virJ .G a s t ro e nPati ents W ithH C VGe n o t yy

59、p e 3o r6 In f ection20 1 51 4 9(6):14 5 4 14 6 1 , .tero 1og y 1 23 HUJ,D OU C E T TEKHA R TLI N GLeta1 .Tr ea t me nto f h epa ti tisCi nch i 1 dr e n:as ystema t icreviewJ .PLoSOne, 2010,5(7):ell542. 1 2 4 HARTWELLD,COOPERK,FRAMPTONGK,e ta 1 .T h e c1 i nic a1 e ff e c ti v e n e s sandcostef f e

60、ct iv e ne s soE H T AS H ,e t a 1 .H e p a t o t o x i c i t ya sfp e g i n t i nf o r t h at i t i s :1nc h i 1 d ce v a 1u a s s e s s ,22 . 12 5e r f e r o r et r e a t measystema renandyot i o na1 faandnt ofc hrticrev iu n gpeo pHe a1t hT5) :i xxK I MS ,T Hr i b a v iro n i ch e p e wa n de C1